Form 4: Natera Clinical Diagnostics President Sells Shares Under Pre-Arranged Trading Plan

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold 3,000 shares of common stock on June 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NTRA), reported the sale of 3,000 shares of Natera common stock.
• The transactions occurred on June 2, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Moshkevich on November 26, 2024.
• The sales were conducted in multiple transactions at weighted average prices ranging from $156.3016 to $159.12 per share.
• Specifically, 1,290 shares were sold at a weighted average price of $156.3016, 1,145 shares at $157.2298, 465 shares at $158.3718, and 100 shares at $159.12.
• Following these transactions, Mr. Moshkevich beneficially owns 133,205 shares of Natera common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under a pre-arranged Rule 10b5-1 trading plan mitigates any immediate negative signal, as such plans are typically set up for personal financial planning purposes and not in response to new company developments.

Positives

• The sale of shares was conducted pursuant to a Rule 10b5-1 trading plan, which indicates a pre-scheduled transaction rather than a reactive sale based on new, non-public information.

Negatives

• The reduction in direct insider ownership, even if pre-planned, can sometimes be perceived negatively by investors as it decreases the alignment of interests between management and shareholders.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Form 4 filings primarily report individual insider transactions and do not typically provide broader industry context or trends. This filing reflects a routine insider stock sale within the biotechnology and diagnostics sector.

Stakeholder Impact

• Shareholders: May view the reduction in insider ownership with slight concern, though the pre-arranged nature of the sale (10b5-1 plan) lessens the potential negative interpretation.

Key Dates

Recommendation

Keywords

Natera, NTRA, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Solomon Moshkevich, Beneficial Ownership, Clinical Diagnostics